Acumen Pharmaceuticals, Inc.
ABOS
$1.11
$0.098.82%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -95.39% | -67.57% | -39.51% | -24.21% | -22.20% |
| Total Depreciation and Amortization | -3.26% | -10.82% | -15.15% | -4.35% | 8.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.53% | 18.45% | 2.22% | 38.94% | 48.17% |
| Change in Net Operating Assets | 201.42% | 790.39% | 11,177.27% | -105.55% | -3.01% |
| Cash from Operations | -100.20% | -46.48% | -31.71% | -37.05% | -22.50% |
| Capital Expenditure | 23.81% | 28.57% | 68.10% | 78.95% | 86.96% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 127.99% | 78.77% | -2,462.75% | -5,636.79% | -536.27% |
| Cash from Investing | 127.98% | 78.75% | -2,522.61% | -5,995.08% | -538.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.53% | -93.73% | 3,256.22% | 3,241.62% | 3,038.44% |
| Repurchase of Common Stock | 89.49% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 51.68% | -338.51% | -355.26% | -- | -- |
| Cash from Financing | -95.43% | -71.55% | 4,107.55% | 3,966.04% | 3,784.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.37% | 1.20% | 73.22% | -0.23% | -893.32% |
